Correction to "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?"

Article information

Child Kidney Dis. 2026;30(1):69-69

Publication date (electronic) : 2026 January 12

doi : https://doi.org/10.3339/ckd.23.021.c1

¹Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Republic of Korea

²Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Republic of Korea

See the letter "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?" on page 76.

Child Kidney Dis 2023;27(2):76-81.

https://doi.org/10.3339/ckd.23.021

In the article titled “Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?” [1] published December 31, 2023, errors were identified in an author name. The incorrect name has been corrected for accuracy. This article has been corrected online.

References

1. Baek HS, Cho MH. Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease? Child Kidney Dis 2023;27:76–8. 10.3339/ckd.23.021.

Article information Continued

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited